Shopping Cart
Remove All
Your shopping cart is currently empty
Naratuximab emtansine
😃Good
Catalog No. T9901A-223Cas No. 1607824-64-5
Alias IMGN529, Debio 1562
Naratuximab emtansine (IMGN529) is a CD37-targeted antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody linked to the microtubule-disrupting agent DM1. This compound demonstrates high affinity and specificity to CD37, facilitating the internalization, processing, and intracellular release of DM1. The functional activity of DM1 enables it to induce cell cycle arrest and apoptosis by disrupting microtubule assembly.
Naratuximab emtansine
Naratuximab emtansine
😃Good
Catalog No. T9901A-223Alias IMGN529, Debio 1562Cas No. 1607824-64-5
Naratuximab emtansine (IMGN529) is a CD37-targeted antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody linked to the microtubule-disrupting agent DM1. This compound demonstrates high affinity and specificity to CD37, facilitating the internalization, processing, and intracellular release of DM1. The functional activity of DM1 enables it to induce cell cycle arrest and apoptosis by disrupting microtubule assembly.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Naratuximab emtansine (IMGN529) is a CD37-targeted antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody linked to the microtubule-disrupting agent DM1. This compound demonstrates high affinity and specificity to CD37, facilitating the internalization, processing, and intracellular release of DM1. The functional activity of DM1 enables it to induce cell cycle arrest and apoptosis by disrupting microtubule assembly. |
| In vitro | Naratuximab emtansine (IMGN529) (0.125 nM, 24 h) administered alone can induce activation of caspases 3/7 in DLBCL cell lines, an effect significantly enhanced by the presence of rituximab (2 nM), which further induces an increase in cleaved PARP levels. Additionally, Naratuximab emtansine (IMGN529) (0-3 ng/mL) demonstrates dose-dependent antibody-dependent cell-mediated cytotoxicity (ADCC) activity in U-2932 and SU-DHL-4 cell lines. |
| In vivo | A single treatment of Naratuximab emtansine (IMGN529) at a dosage of 10 mg/kg (administered as a one-time injection) showed no activity against U-2932 tumors alone. However, when combined with rituximab, there was a significant enhancement in antitumor activity. Throughout the study, no noticeable toxicity or weight loss was observed in female U2932 CB.17-SCID mice. |
| Synonyms | IMGN529, Debio 1562 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | ＜ 1.0 EU/mg |
| Target | CD37 |
| Cas No. | 1607824-64-5 |
| Storage | -20°C for 1 year | Shipping with blue ice. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Naratuximab emtansine | purchase Naratuximab emtansine | Naratuximab emtansine cost | order Naratuximab emtansine | Naratuximab emtansine in vivo | Naratuximab emtansine in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.